在儿科胚胎瘤中探索维护疗法,使用多层 Розет
Mohamed M Ahmed1, Fernando Carceller1,2, Leslie R Bridges3
1Children and Young People's Unit, The Royal Marsden NHS Foundation Trust.
Journal of pediatric hematology/oncology
|April 7, 2025
概括
具有多层红体 (ETMR) 的胚胎瘤具有攻击性. 这项案例研究显示,一个患者通过一种新的维持疗法实现了长期缓解,这表明了潜在的新治疗途径.
科学领域:
- 儿科瘤学 儿科瘤学
- 神经瘤学神经瘤学
- 遗传学 是一个遗传学.
背景情况:
- 带有多层红的胚胎瘤 (ETMR) 是罕见的,侵袭性的儿科脑瘤.
- 从历史上看,ETMR的生存率非常差,通常在1年内不到14%.
- 最近的研究表明,生存率有所改善,但长期的结果仍然是一个挑战.
研究的目的:
- 在婴儿中报告ETMR病例.
- 评估一种新的维持疗法方案的可行性和安全性.
- 评估使用这种疗法治疗的患者的长期结果.
主要方法:
- 通过染色体19微RNA集群放大证实ETMR的诊断.
- 治疗包括手术,高剂量化疗与干细胞救援,和质子疗法.
- 进行了12个月的肠内托波特干,口服甲酸和口服cis-retinoic acid的维持疗程.
主要成果:
- 患者在初始治疗后获得了无病状态.
- 维护疗法耐受性良好,副作用可控.
- 患者在维持治疗后的32个月内 (从最初的呈现开始的50个月) 保持无进展.
结论:
- 这一案例证明了对ETMR的多剂维持疗法的可行性和安全性.
- 观察到的长期缓解表明,这种方法可能会改善ETMR儿童的结果.
- 需要进一步的研究来确定这种维护策略的有效性.
相关概念视频
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...